Alliance Global Partners Upgrades BioCardia (NASDAQ:BCDA) to “Strong-Buy”

Alliance Global Partners upgraded shares of BioCardia (NASDAQ:BCDA) from a hold rating to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of BioCardia in a research report on Wednesday, December 18th.

BioCardia Price Performance

Shares of NASDAQ:BCDA opened at $2.47 on Thursday. The firm has a market capitalization of $11.31 million, a price-to-earnings ratio of -0.59 and a beta of 1.26. The business’s 50 day simple moving average is $2.20 and its 200-day simple moving average is $2.51. BioCardia has a 12 month low of $1.63 and a 12 month high of $8.85.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.